miR‑489 promotes apoptosis and inhibits invasiveness of glioma cells by targeting PAK5/RAF1 signaling pathways Retraction in /10.3892/or.2023.8564

Wang,Wei; Zhang,Luyang; Gao,Wei; Zhang,Dongyong; Zhao,Zilong; Bao,Yijun

doi:10.3892/or.2019.7381

miR‑489 promotes apoptosis and inhibits invasiveness of glioma cells by targeting PAK5/RAF1 signaling pathways

Retraction in: /10.3892/or.2023.8564

Authors:
- Wei Wang
- Luyang Zhang
- Wei Gao
- Dongyong Zhang
- Zilong Zhao
- Yijun Bao
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: October 22, 2019 https://doi.org/10.3892/or.2019.7381
Pages: 2390-2401
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma patients receiving therapy are at a high risk of relapse and rapid progression and, thus, more effective treatments are required. The aim of the present study was to determine the suppressive role of miR‑489 as an alternative therapeutic target for preventing glioma progression. The results of the present study demonstrated that patients with relatively lower levels of expression of miR‑489 had more favorable clinical outcomes. Furthermore, miR‑489 expression was inversely correlated with p21‑activated kinase 5 (PAK5) mRNA expression levels in glioma specimens. A dual luciferase reporter assay revealed that miR‑489 suppressed PAK5 expression by directly targeting the PAK5 3'‑untranslated region. The effects of miR‑489 on cell viability were measured using MTT and Cell Counting Kit‑8 assays. The results demonstrated that ectopic expression of miR‑489 mimic decreased cell viability by interfering with cyclin D1 and c‑Myc signaling. Additionally, the effect of miR‑489 on apoptosis was determined using Hoechst 33258 staining and flow cytometry. The results demonstrated that miR‑489 decreased the activity of RAF1, reduced Bcl‑2 and promoted Bax expression, resulting in increased cell apoptosis. Furthermore, the effect of miR‑489 mimic on cellular motility was assessed using migration and invasion assays. miR‑489 was shown to abolish the PAK5/RAF1/MMP2 pathway, resulting in decreased cell invasion ability. These results indicated that miR‑489 may be involved in PAK5‑mediated regulation of glioma progression, demonstrating the potential therapeutic benefits of targeting miR‑489 in glioma.

View Figures

View References

1	Kumar V, Kumar V, McGuire T, Coulter DW, Sharp JG and Mahato RI: Challenges and recent advances in medulloblastoma therapy. Trends Pharmacol Sci. 38:1061–1084. 2017. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lapointe S, Perry A and Butowski NA: Primary brain tumours in adults. Lancet. 392:432–446. 2018. View Article : Google Scholar : PubMed/NCBI
4	Lombardi MY and Assem M: Glioblastoma Genomics: A very complicated storyGlioblastoma. De Vleeschouwer S: Chapter 1. Codon Publications; Brisbane (AU): 2017, https://www.ncbi.nlm.nih.gov/books/NBK470004/doi: 10.15586/codon.glioblastoma.2017.ch1.
5	Ha BH, Morse EM, Turk BE and Boggon TJ: Signaling, regulation, and specificity of the type II p21-activated kinases. J Biol Chem. 290:12975–12983. 2015. View Article : Google Scholar : PubMed/NCBI
6	Wen YY, Zheng JN and Pei DS: An oncogenic kinase: Putting PAK5 forward. Expert Opin Ther Targets. 18:807–815. 2014. View Article : Google Scholar : PubMed/NCBI
7	Gu X, Wang C, Wang X, Ma G, Li Y, Cui L, Chen Y, Zhao B and Li K: Efficient inhibition of human glioma development by RNA interference-mediated silencing of PAK5. Int J Biol Sci. 11:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
8	Han ZX, Wang XX, Zhang SN, Wu JX, Qian HY, Wen YY, Tian H, Pei DS and Zheng JN: Downregulation of PAK5 inhibits glioma cell migration and invasion potentially through the PAK5-Egr1-MMP2 signaling pathway. Brain Tumor Pathol. 31:234–241. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wang X: Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-ligation studies. Bioinformatics. 32:1316–1322. 2016. View Article : Google Scholar : PubMed/NCBI
10	Wen MM: Getting miRNA therapeutics into the target cells for neurodegenerative diseases: A mini-review. Front Mol Neurosci. 9:1292016. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Wang Q, Wang F, Zhang X, Zhang L, Tang Y and Wang S: LncRNA LINC01446 promotes glioblastoma progression by modulating miR-489-3p/TPT1 axis. Biochem Biophys Res Commun. 503:1484–1490. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xu D, Liu R, Meng L, Zhang Y, Lu G and Ma P: Long non-coding RNA ENST01108 promotes carcinogenesis of glioma by acting as a molecular sponge to modulate miR-489. Biomed Pharmacother. 100:20–28. 2018. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Ma X, Wang Y and Li G: MiR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway. Biomed Pharmacother. 93:435–443. 2017. View Article : Google Scholar : PubMed/NCBI
14	Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S Waszkowycz B, Miller CJ and Brognard J: Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci USA. 110:12426–12431. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wong N and Wang X: MiRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wu X, Carr HS, Dan I, Ruvolo PP and Frost JA: P21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem. 105:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
17	Chai Z, Fan H, Li Y, Song L, Jin X, Yu J, Li Y, Ma C and Zhou R: MiR-1908 as a novel prognosis marker of glioma via promoting malignant phenotype and modulating SPRY4/RAF1 axis. Oncol Rep. 38:2717–2726. 2017. View Article : Google Scholar : PubMed/NCBI
18	Lee SH, Lee EH, Lee SH, Lee YM, Kim HD and Kim YZ: Epigenetic role of histone 3 lysine methyltransferase and demethylase in regulating apoptosis predicting the recurrence of atypical meningioma. J Korean Med Sci. 30:1157–1166. 2015. View Article : Google Scholar : PubMed/NCBI
19	Filbin MG and Suva ML: Gliomas genomics and epigenomics: Arriving at the start and knowing it for the first time. Annu Rev Pathol. 11:497–521. 2016. View Article : Google Scholar : PubMed/NCBI
20	Alifieris C and Trafalis DT: Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82. 2015. View Article : Google Scholar : PubMed/NCBI
21	Karsy M, Guan J, Sivakumar W, Neil JA, Schmidt MH and Mahan MA: The genetic basis of intradural spinal tumors and its impact on clinical treatment. Neurosurg Focus. 39:E32015. View Article : Google Scholar : PubMed/NCBI
22	Soni M, Patel Y, Markoutsa E, Jie C, Liu S, Xu P and Chen H: Autophagy, cell viability, and chemoresistance are regulated by miR-489 in breast cancer. Mol Cancer Res. 16:1348–1360. 2018. View Article : Google Scholar : PubMed/NCBI
23	Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, Cai Y, Li X, Xing H, Shi M, et al: MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 588:2009–2015. 2014. View Article : Google Scholar : PubMed/NCBI
24	Chen X, Wang YW, Xing AY, Xiang S, Shi DB, Liu L, Li YX and Gao P: Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. J Pathol. 239:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
25	Patel Y, Shah N, Lee JS, Markoutsa E, Jie C, Liu S, Botbyl R, Reisman D, Xu P and Chen H: A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. Oncotarget. 7:18295–18308. 2016. View Article : Google Scholar : PubMed/NCBI
26	Kuppa SS, Jia W, Liu S, Nguyen H, Smyth SS, Mills GB, Dobbin KK, Hardman WJ and Murph MM: Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. Cancer Lett. 432:84–92. 2018. View Article : Google Scholar : PubMed/NCBI
27	Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J, Zhou L, Zheng SS and Jiang B: MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. Clin Transl Oncol. 20:703–712. 2018. View Article : Google Scholar : PubMed/NCBI
28	Tao Y, Han T, Zhang T, Ma C and Sun C: LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal cancer via TWIST1/EMT signaling pathway. Oncotarget. 8:36410–36422. 2017. View Article : Google Scholar : PubMed/NCBI
29	Liu G, Wang H, Fu JD, Liu JY, Yan AG and Guan YY: A five-miRNA expression signature predicts survival in hepatocellular carcinoma. APMIS. 125:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
30	Chen X, Dong H, Liu S, Yu L, Yan D, Yao X, Sun W, Han D and Gao G: Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway. Am J Transl Res. 9:90–102. 2017.PubMed/NCBI
31	Dong P, Xiong Y, Yue J, Hanley SJB and Watari H: B7H3 As a promoter of metastasis and promising therapeutic target. Front Oncol. 8:2642018. View Article : Google Scholar : PubMed/NCBI
32	Wu H, Xiao Z, Zhang H, Wang K, Liu W and Hao Q: MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anticancer Drugs. 25:799–809. 2014. View Article : Google Scholar : PubMed/NCBI
33	Pashaei E, Pashaei E, Ahmady M, Ozen M and Aydin N: Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy. PLoS One. 12:e01795432017. View Article : Google Scholar : PubMed/NCBI
34	Kumar R, Sanawar R, Li X and Li F: Structure, biochemistry, and biology of PAK kinases. Gene. 605:20–31. 2017. View Article : Google Scholar : PubMed/NCBI
35	Rane CK and Minden A: P21 activated kinase signaling in cancer. Semin Cancer Biol. 54:40–49. 2018. View Article : Google Scholar : PubMed/NCBI
36	Zhang YC, Huo FC, Wei LL, Gong CC, Pan YJ, Mou J and Pei DS: PAK5-mediated phosphorylation and nuclear translocation of NF-kappaB-p65 promotes breast cancer cell proliferation in vitro and in vivo. J Exp Clin Cancer Res. 36:1462017. View Article : Google Scholar : PubMed/NCBI
37	Ismail AF, Oskay Halacli S, Babteen N, De Piano M, Martin TA, Jiang WG, Khan MS, Dasgupta P and Wells CM: PAK5 mediates cell: Cell adhesion integrity via interaction with E-cadherin in bladder cancer cells. Biochem J. 474:1333–1346. 2017. View Article : Google Scholar : PubMed/NCBI
38	Aburatani T, Inokuchi M, Takagi Y, Ishikawa T, Okuno K, Gokita K, Tomii C, Tanioka T, Murase H, Otsuki S, et al: High expression of P21-activated kinase 5 protein is associated with poor survival in gastric cancer. Oncol Lett. 14:404–410. 2017. View Article : Google Scholar : PubMed/NCBI
39	Zheng J, Li XD, Wang P, Liu XB, Xue YX, Hu Y, Li Z, Li ZQ, Wang ZH and Liu YH: CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget. 6:25339–25355. 2015. View Article : Google Scholar : PubMed/NCBI